CYPHERPUNK TECHNOLOGIES INC. Research and Development Expense
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Research and Development Expense of $197.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- CYPHERPUNK TECHNOLOGIES INC. research and development expense for the quarter ending 2026-06-30 was $197.00K, a 98.13% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. research and development expense for the quarter ending 2026-03-31 was $161.00K, a 98.75% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. research and development expense for the quarter ending 2025-12-31 was $975.00K, a 92.56% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. research and development expense for the quarter ending 2025-09-30 was $1.25M, a 91.64% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. research and development expense for fiscal 2025 was $25.67M, a 55.13% decline from fiscal 2024.
- CYPHERPUNK TECHNOLOGIES INC. research and development expense for fiscal 2024 was $57.21M, a 21.88% decline from fiscal 2023.
- CYPHERPUNK TECHNOLOGIES INC. research and development expense for fiscal 2023 was $73.23M, a 62.87% increase from fiscal 2022.
- CYPHERPUNK TECHNOLOGIES INC. research and development expense for fiscal 2022 was $44.97M, a 39.82% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $197.00K 10-Q · filed 2026-08-12 | $358.00K 10-Q · filed 2026-08-12 | $1.33M derived: sum of 3 quarters · filed 2026-08-12 | $2.58M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $161.00K 10-Q · filed 2026-05-14 | $1.14M derived: sum of 2 quarters · filed 2026-05-14 | $2.38M derived: sum of 3 quarters · filed 2026-05-14 | $12.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $975.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.22M derived: sum of 2 quarters · filed 2026-03-16 | $12.76M derived: sum of 3 quarters · filed 2026-08-12 | $25.67M 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.25M 10-Q · filed 2025-11-12 | $11.78M derived: sum of 2 quarters · filed 2026-08-12 | $24.70M 10-Q · filed 2025-11-12 | $37.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $10.54M 10-Q · filed 2026-08-12 | $23.45M 10-Q · filed 2026-08-12 | $36.56M derived: sum of 3 quarters · filed 2026-08-12 | $51.48M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $12.91M 10-Q · filed 2026-05-14 | $26.02M derived: sum of 2 quarters · filed 2026-05-14 | $40.94M derived: sum of 3 quarters · filed 2026-05-14 | $58.82M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $13.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $28.03M derived: sum of 2 quarters · filed 2026-03-16 | $45.91M derived: sum of 3 quarters · filed 2026-03-16 | $57.21M 10-K · filed 2026-03-16 |
| 2024-09-30 | $14.91M 10-Q · filed 2025-11-12 | $32.80M derived: sum of 2 quarters · filed 2025-11-12 | $44.10M 10-Q · filed 2025-11-12 | $55.78M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $17.89M 10-Q · filed 2025-08-14 | $29.18M 10-Q · filed 2025-08-14 | $40.87M derived: sum of 3 quarters · filed 2025-08-14 | $52.37M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $11.30M 10-Q · filed 2025-05-13 | $22.98M derived: sum of 2 quarters · filed 2025-05-13 | $34.49M derived: sum of 3 quarters · filed 2025-05-13 | $45.59M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $11.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $23.19M derived: sum of 2 quarters · filed 2025-03-26 | $34.29M derived: sum of 3 quarters · filed 2025-03-26 | $73.23M 10-K · filed 2025-03-26 |
| 2023-09-30 | $11.50M 10-Q · filed 2024-11-13 | $22.61M derived: sum of 2 quarters · filed 2024-11-13 | $61.55M 10-Q · filed 2024-11-13 | $72.58M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $11.10M 10-Q · filed 2024-08-12 | $50.05M 10-Q · filed 2024-08-12 | $61.08M derived: sum of 3 quarters · filed 2024-08-12 | $73.18M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $38.94M 10-Q · filed 2024-05-13 | $49.98M derived: sum of 2 quarters · filed 2024-05-13 | $62.08M derived: sum of 3 quarters · filed 2024-05-13 | $76.12M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $11.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $23.14M derived: sum of 2 quarters · filed 2024-03-18 | $37.18M derived: sum of 3 quarters · filed 2024-03-18 | $44.97M 10-K · filed 2024-03-18 |
| 2022-09-30 | $12.10M 10-Q · filed 2023-11-13 | $26.15M derived: sum of 2 quarters · filed 2023-11-13 | $33.93M 10-Q · filed 2023-11-13 | $42.00M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $14.04M 10-Q · filed 2023-08-14 | $21.83M 10-Q · filed 2023-08-14 | $29.90M derived: sum of 3 quarters · filed 2023-08-14 | $39.98M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $7.78M 10-Q · filed 2023-05-15 | $15.85M derived: sum of 2 quarters · filed 2023-05-15 | $25.93M derived: sum of 3 quarters · filed 2023-05-15 | $33.14M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $8.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $18.15M derived: sum of 2 quarters · filed 2023-03-24 | $25.35M derived: sum of 3 quarters · filed 2023-03-24 | $32.16M 10-K · filed 2023-03-24 |
| 2021-09-30 | $10.08M 10-Q · filed 2022-11-14 | $17.28M derived: sum of 2 quarters · filed 2022-11-14 | $24.09M 10-Q · filed 2022-11-14 | $29.19M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $7.21M 10-Q · filed 2022-08-12 | $14.01M 10-Q · filed 2022-08-12 | $19.11M derived: sum of 3 quarters · filed 2022-08-12 | $24.48M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $6.81M 10-Q · filed 2022-05-13 | $11.91M derived: sum of 2 quarters · filed 2022-05-13 | $17.28M derived: sum of 3 quarters · filed 2022-05-13 | $22.63M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $10.47M derived: sum of 2 quarters · filed 2022-03-11 | $15.82M derived: sum of 3 quarters · filed 2022-03-11 | $20.42M 10-K · filed 2022-03-11 |
| 2020-09-30 | $5.37M 10-Q · filed 2021-11-12 | $10.72M derived: sum of 2 quarters · filed 2021-11-12 | $15.32M 10-Q · filed 2021-11-12 | $20.99M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $5.35M 10-Q · filed 2021-08-13 | $9.95M 10-Q · filed 2021-08-13 | $15.62M derived: sum of 3 quarters · filed 2021-08-13 | $21.39M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $4.60M 10-Q · filed 2021-05-14 | $10.27M derived: sum of 2 quarters · filed 2021-05-14 | $16.04M derived: sum of 3 quarters · filed 2021-05-14 | $22.18M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $11.44M derived: sum of 2 quarters · filed 2021-03-12 | $17.58M derived: sum of 3 quarters · filed 2021-03-12 | $24.37M 10-K · filed 2021-03-12 |
| 2019-09-30 | $5.77M 10-Q · filed 2020-11-12 | $11.91M derived: sum of 2 quarters · filed 2020-11-12 | $18.70M 10-Q · filed 2020-11-12 | $25.61M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $6.14M 10-Q · filed 2020-08-13 | $12.93M 10-Q · filed 2020-08-13 | $19.83M derived: sum of 3 quarters · filed 2020-08-13 | $26.29M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $6.79M 10-Q · filed 2020-05-14 | $13.70M derived: sum of 2 quarters · filed 2020-05-14 | $20.16M derived: sum of 3 quarters · filed 2020-05-14 | $24.39M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | $6.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $13.37M derived: sum of 2 quarters · filed 2020-03-16 | $17.60M derived: sum of 3 quarters · filed 2020-03-16 | $21.83M 10-K · filed 2020-03-16 |
| 2018-09-30 | $6.46M 10-Q · filed 2019-11-14 | $10.69M derived: sum of 2 quarters · filed 2019-11-14 | $14.92M 10-Q · filed 2019-11-14 | $19.34M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $4.23M 10-Q · filed 2019-08-09 | $8.46M 10-Q · filed 2019-08-09 | $12.88M derived: sum of 3 quarters · filed 2019-08-09 | $19.68M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $4.23M 10-Q · filed 2019-05-15 | $8.65M derived: sum of 2 quarters · filed 2019-05-15 | $15.45M derived: sum of 3 quarters · filed 2019-05-15 | $20.33M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $4.42M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $11.22M derived: sum of 2 quarters · filed 2019-04-01 | $16.10M derived: sum of 3 quarters · filed 2019-04-01 | $22.50M 10-K · filed 2019-04-01 |
| 2017-09-30 | $6.80M 10-Q · filed 2018-11-09 | $11.68M derived: sum of 2 quarters · filed 2018-11-09 | $18.09M 10-Q · filed 2018-11-09 | $25.51M derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $4.88M 10-Q · filed 2018-08-08 | $11.29M 10-Q · filed 2018-08-08 | $18.71M derived: sum of 3 quarters · filed 2018-08-08 | $24.37M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-03-31 | $6.40M 10-Q/A · filed 2018-08-08 | $13.83M derived: sum of 2 quarters · filed 2018-08-08 | $19.48M derived: sum of 3 quarters · filed 2018-08-08 | $25.61M derived: sum of 4 quarters · filed 2018-08-08 |
| 2016-12-31 | $7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $13.08M derived: sum of 2 quarters · filed 2018-02-23 | $19.20M derived: sum of 3 quarters · filed 2018-02-23 | $23.29M 10-K · filed 2018-02-23 |
| 2016-09-30 | $5.66M 10-Q · filed 2017-11-13 | $11.78M derived: sum of 2 quarters · filed 2017-11-13 | $15.87M 10-Q · filed 2017-11-13 | |
| 2016-06-30 | $6.12M 10-Q · filed 2017-08-11 | $10.21M 10-Q · filed 2017-08-11 | ||
| 2016-03-31 | $4.09M 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |